RPRD1B: A Potential Drug Target and Biomarker for Cell-Cycle-Related and Expression-Elevated Proteins in Tumors

Target Name: RPRD1B

NCBI ID: G58490

RPRD1B

RPRD1B: A Potential Drug Target and Biomarker for Cell-Cycle-Related and Expression-Elevated Proteins in Tumors

Tumors are complex structures that require precise regulation of various cellular processes to maintain their growth and survival. One of the key aspects of tumor development is the cell cycle, which is the process by which cells divide and grow. The cell cycle is closely monitored by a set of proteins that regulate the different stages of cell growth, including G1, S, G2, and M phases. Another important protein that is involved in the cell cycle is the RPRD1B protein. RPRD1B is a cell-cycle-related and expression-elevated protein that is expressed in various tissues and has been associated with various diseases, including cancer.

In this article, we will discuss the biology of RPRD1B, its potential as a drug target and biomarker, and its potential clinical applications.

Biogenesis and Localization

RPRD1B is a 21-kDa protein that is expressed in various tissues, including muscle, pancreas, and brain. It is primarily localized to the nuclei and cytoplasm of cells and is involved in the regulation of the cell cycle. RPRD1B is composed of a unique N-terminal domain that contains a conserved nucleotide-binding oligomerization domain (NBO), which is responsible for its cell-cycle-related functions.

Function and Interaction

RPRD1B is involved in the regulation of the cell cycle at various stages, including G1, S, G2, and M phases. It plays a critical role in the transition from G1 to S phase, where the cell prepares for cell division. RPRD1B is known to interact with various transcription factors, including DNMT1, which is responsible for the removal of DNA methylation in the G1 phase.

In addition to its role in the cell cycle, RPRD1B is also involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. It has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tissues.

Potential Therapeutic Applications

RPRD1B is a potential drug target and biomarker for various diseases, including cancer. Its functions in the cell cycle and its ability to interact with transcription factors make it an attractive target for small molecules that can inhibit its activity.

One of the most promising compounds that can interact with RPRD1B is the drugletanib, which is a small molecule that inhibits the activity of RPRD1B. The results of several studies have shown that drugletanib is effective in inhibiting the growth of various cancer cell lines, including breast, lung, and ovarian cancer cells.

Another potential application of RPRD1B is its use as a biomarker for cancer diagnosis and monitoring. The expression of RPRD1B is often increased in various tissues and has been used as a biomarker for various cancers, including breast, lung, and ovarian cancer.

Conclusion

In conclusion, RPRD1B is a cell-cycle-related and expression-elevated protein that is involved in various cellular processes, including the regulation of the cell cycle and the regulation of various diseases, including cancer. Its functions make it an attractive target for small molecules that can inhibit its activity. The potential applications of RPRD1B as a drug target and biomarker for cancer make it an important area of research for the development of new treatments for these diseases.

Protein Name: Regulation Of Nuclear Pre-mRNA Domain Containing 1B

Functions: Interacts with phosphorylated C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and participates in dephosphorylation of the CTD by RPAP2. Transcriptional regulator which enhances expression of CCND1. Promotes binding of RNA polymerase II to the CCDN1 promoter and to the termination region before the poly-A site but decreases its binding after the poly-A site. Prevents RNA polymerase II from reading through the 3' end termination site and may allow it to be recruited back to the promoter through promotion of the formation of a chromatin loop. Also enhances the transcription of a number of other cell cycle-related genes including CDK2, CDK4, CDK6 and cyclin-E but not CDKN1A, CDKN1B or cyclin-A. Promotes cell proliferation

The "RPRD1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPRD1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets